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PCardiac Imaging
The Binary Endocardial Appearance
Is a Poor Discriminator of Anderson-Fabry
Disease From Familial Hypertrophic Cardiomyopathy
Stavros Kounas, MD,* Camelia Demetrescu, BSC, MD,* Antonios A. Pantazis, MD,*
Andre Keren, MD,† Philip J. Lee, DM, FRCPCH, FRCP,‡
Derralynn Hughes, MA, DPHIL, MRCP, MRCPATH,§ Atul Mehta, MA, MD, FRCP, FRCPATH,§
Perry Mark Elliott, MBBS, MD, FRCP, FACC, FESC*
London, United Kingdom; and Jerusalem, Israel
Objectives We compared the frequency of a binary endocardial appearance in patients with hypertrophic cardiomyopathy
(HCM) and Anderson-Fabry disease (AFD).
Background A recent study suggested that a binary endocardial appearance is a highly sensitive and specific discriminator of
AFD from other causes of hypertrophic cardiomyopathy (HCM).
Methods Fourteen patients with AFD (55.4  9.9 years, 9 men) and 14 patients with HCM (57.2  10.9 years, 9 men)
were randomly selected from a dedicated patient database. Two-dimensional echo images were blindly reviewed
by 2 experienced echocardiographers.
Results Maximum left ventricular (LV) wall thickness, LV end-systolic dimension, fractional shortening, and left atrial size
were similar in the 2 patient groups. The LV end-diastolic dimension was smaller in patients with HCM (p 
0.04). A binary sign was present in 8 of 28 patients (29%). The sensitivity and specificity of the binary sign as a
discriminator of AFD from HCM were 35% and 79%, respectively. A binary sign was present in only 1 patient
with LV wall thickness 15 mm.
Conclusions The binary endocardial appearance lacks sufficient sensitivity and specificity to be used as an echocardiographic
screening tool. (J Am Coll Cardiol 2008;51:2058–61) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.02.046e
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bypertrophic cardiomyopathy (HCM), defined as left
entricular hypertrophy (LVH) in the absence of a
emodynamic abnormality sufficient to cause the ob-
erved degree of myocardial thickening, has a population
requency of 1 in 500 persons (1). Several studies have
uggested that between 2% and 4% of individuals fulfill-
ng conventional echocardiographic criteria for HCM
ave Anderson-Fabry disease (AFD), an X-linked lyso-
omal storage disorder caused by a deficiency of
-galactosidase A (-Gal) (2,3). Current noninvasive
creening methods for AFD require analysis of plasma or
eucocyte -Gal activity and direct sequencing of the
rom the *Heart Hospital, University College London, London, United Kingdom;
Hadassah University Hospital, Jerusalem, Israel; ‡Charles Dent Metabolic Unit,
ational Hospital for Neurology and Neurosurgery, London, United Kingdom; and
he §Lysosomal Storage Disorders Unit, Royal Free Hospital, London, United
ingdom. Dr. Elliott has received consultancies and unrestricted education grants
rom Shire Human Genetics Therapies and Genzyme, Inc.s
Manuscript received November 12, 2007; revised manuscript received January 24,
008, accepted February 5, 2008.ncoding gene. A recent study has suggested that a binary
ppearance of the left ventricular endocardial border on
-dimensional (2D) echocardiography is a highly sensi-
ive and specific discriminator of AFD from HCM (4).
he aim of the present study was to test this sign in a
ouble-blind manner in a referral population of patients
ith HCM and AFD.
ethods
atient population. Two groups of patients with HCM and
FD were randomly selected from a dedicated database of
atients followed at The Heart Hospital, London, U.K.
atients were matched for age, gender and maximum left
entricular (LV) wall thickness. The diagnosis of HCM was
ased on the presence of a maximum LV wall thickness of15
m (1) or on familial diagnostic criteria when maximum LV
all thickness was 15 mm (5). The diagnosis of AFD was
ased on leucocyte -Gal activity and deoxyribonucleic acid
equencing of the encoding gene. All AFD patients were
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orporation, Cambridge, Massachusetts] or Replagal [Shire
uman Genetic Therapies, Inc., Cambridge, Massachusetts])
t the Lysosomal Storage Diseases Unit, The Royal Free
ospital, London, United Kingdom, or the National Hospital
or Neurology and Neurosurgery, London, United
ingdom.
chocardiography. All echocardiographic studies were
erformed using a General Electric Vivid 7 (Milwaukee,
isconsin) or a Phillips Sonos 7500 (Best, the Nether-
ands) ultrasound system. The 2D images from the
arasternal short-axis and the standard apical views were
eviewed by 2 experienced echocardiographers blinded to
he patients’ diagnoses and clinical details. All data were
tored as digital recordings. No off-line changes were
ade to imaging settings, including 2D gain and com-
ression. The binary sign was defined as an echo-bright
ndocardium with an adjacent hyporeflective subendocar-
ial layer, discriminating it from the myocardial midwall
t end-diastole. The presence of the binary sign was
oted, and in cases of disagreement consensus was
eached with the help of a third experienced reviewer.
Left ventricular septal, posterior, and lateral wall thick-
ess, left ventricular end-diastolic and -systolic dimen-
ions, LV fractional shortening (FS), and left atrial
iameter (LAD) were measured using established meth-
ds (6). Maximum wall thickness was defined as the
reatest measured at any LV segment. Left ventricular
utflow tract (LVOT) obstruction was defined as a peak
ressure gradient of 30 mm Hg at rest or upon Valsalva
rovocation measured with continuous-wave Doppler. In
ases with a maximum LV wall thickness of 13 mm,
symmetrical septal and concentric patterns were defined
sing basal septal to posterior wall thickness ratio with a
ut-off value of 1.3.
tatistical analysis. Continuous variables are presented
s mean  SD and categoric data as proportion or
ercentage. Two-tailed unpaired Student t test was used
o compare continuous variables. Comparisons of per-
entages between groups were performed using the Fisher
xact test. A value of p  0.05 was considered to be
ignificant.
The kappa () statistic was used to describe interob-
erver agreement. To assess intraobserver agreement, 10
andomly selected studies were reviewed after 6 months
y 1 echocardiographer. A value of 0.6 was considered
o indicate good agreement between analyses.
esults
he study population comprised of 14 patients with AFD
mean age 55.4  9.9 years, 9 men and 5 women) and 14
atients with HCM (mean age 57.2  10.9 years, 9 men
nd 5 women) (Table 1).
Two (14%) AFD patients had a normal LV wall
hickness (13 mm), 3 (21%) had a maximum LV wall
v
vhickness of 13 to 14 mm, and 9
64%) had a wall thickness of
15 mm. The LVH was con-
entric in all AFD patients with
he exception of a 40-year-old
an with eccentric hypertrophy
f the LV basal posterior wall.
o patient with AFD had
VOT obstruction.
Four HCM patients (29%)
ad a maximum wall thickness
f 13 to 14 mm and 10 (71%)
ad a wall thickness of 15
m. Thirteen of the 14 patients
93%) with familial HCM had
symmetric septal hypertrophy;
he remainder had concentric LVH. Four of the 14 patients
29%) had resting or provocable LVOT obstruction.
Maximum LV wall thickness, left ventricular end-
ystolic dimension, FS, and LAD were similar in the 2
atient groups. An LVOT obstruction tended to be more
ommon (p  0.09) and the left ventricular end-diastolic
imension was smaller (p  0.04) in patients with HCM
Table 1).
The presence of a binary endocardial appearance was
oted in 9 of 28 patients (32%) by the first reviewer and
n 5 of 28 patients (18%) by the second reviewer.
isagreement between the 2 investigators was found in 6
f 28 (21%) of the cases, with a  statistic of 0.44. After
onsensus was reached, a binary sign was considered to be
resent in 8 of 28 patients (29%). Intraobserver disagree-
ent was 30%, with a calculated  statistic of 0.35.
emographic and Echocardiographic Data
Table 1 Demographic and Echocardiographic Data
Parameters AFD HCM p Value
n 14 14
Men/women 9/5 9/5 1.0
Age (yrs)
Men 52.1 10.7 (39–68) 53.4 10.4 (41–71) 0.73
Women 61.4 4.8 (54–67) 64 8.9 (50–71) 0.58
All 55.4 9.9 (39–68) 57.2 10.9 (41–71) 0.65
Max LVWT (mm) 15.8 3.6 (10–22) 15.7 2.1 (13–20) 0.95
Binary sign 5/14 (35%) 3/14 (21%) 0.67
LVEDD (mm) 47.3 4.4 43.6 4.7 0.04
LVESD (mm) 29.2 3.3 28.2 4.8 0.53
FS (%) 0.38 0.05 0.35 0.06 0.27
LAD (mm) 42.6 6.8 41.7 5.7 0.72
LVOTO 0/14 (0%) 4/14 (29%) 0.09
LVH 12/14 (86%) 14/14 (100%) 0.48
Concentric LVH 11/12* (92%) 1/14 (7%) 0.001
ASH 0/12* (0%) 13/14 (92%) 0.001
oncentric LVH defined as septal to posterior wall thickness1.3mm. *Of those patients with LVH.
AFD  Anderson-Fabry disease; ASH  asymmetrical septal hypertrophy, defined as septal to
osterior wall thickness 1.3 mm; FS  fractional shortening; HCM  hypertrophic cardiomyop-
thy; LAD  left atrial diameter; LVEDD  left ventricular end-diastolic dimension; LVESD  left
Abbreviations
and Acronyms
AFD  Anderson-Fabry
disease
-Gal  -galactosidase A
FS  fractional shortening
HCM  hypertrophic
cardiomyopathy
LAD  left atrial diameter
LV  left ventricular
LVH  left ventricular
hypertrophy
LVOT  left ventricular
outflow tractentricular end-systolic dimension; LVH  left ventricula
entricular outflow tract obstruction 30 mm Hg; LVWT r hypertrophy 13 mm; LVOTO  left
left ventricular wall thickness.
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Echocardiography in Anderson-Fabry Disease May 27, 2008:2058–61The sensitivity and specificity of the binary sign as a
iscriminator of AFD from HCM were 35% and 79%,
espectively (Table 2). Among patients with LVH 15
m, the sensitivity was higher (44%), but with a lower
pecificity (70%). A binary sign was present in only 1
atient with LV wall thickness 15 mm.
iscussion
nderson-Fabry disease accounts for between 2% and 4%
f cases of otherwise unexplained LVH (2,3). Correct
iagnosis is important, because patient and family coun-
eling differs from typical autosomal dominant familial
CM and potentially beneficial enzyme replacement
herapy is available (7,8). The identification of AFD in
CM patients can be challenging, particularly in affected
omen, who frequently have leucocyte -Gal activity
ithin the normal range (9). Genetic testing overcomes
his problem but is costly and impractical in large referral
ractices. The use of endomyocardial biopsies as a screen-
ng tool to detect characteristic histologic abnormalities is
imited by its invasive nature and potential hazards.
As this study confirms, there are a number of features
hat should raise suspicion of AFD on transthoracic
chocardiography. Left ventricular hypertrophy is typi-
Figure 1 Apical View of a Patient
With Anderson-Fabry Disease
Left ventricular hypertrophy is present with no binary endocardial appearance.
ensitivity and Specificityf the B nary Endocardial Appearance
Table 2 Sensitivity and Specificityof the Binary Endocardial Appearance
Maximum LVWT
<15 mm >15 mm Overall
AFD No. of patients 5 9 14
Binary sign 1 4 5
Sensitivity 20% 44% 35%
HCM No. of patients 4 10 14
Binary sign 0 3 3
Specificity 100% 70% 79%
bbreviations as in Table 1.aally concentric, and cardiac valves are often abnormal
ith leaflet thickening and redundancy (10). Indexes of
lobal systolic function remain normal until the late stage
f the disease, but early regional posterior-lateral wall
bnormalities may be present (11). Finally, resting
VOT obstruction is uncommon in AFD cardiomyopa-
hy (12). However, these features are nonspecific and can
e seen in patients with other causes of LVH, including
utations in cardiac sarcomeric protein genes.
Recently, Pieroni et al. (4) reported a high prevalence
f a binary endocardial appearance in the left ventricle
and less commonly in the right ventricle). They sug-
ested that this is caused by increased glycosphingolipid
n the subendocardial layers of the myocardium. In their
tudy, this feature had a sensitivity of 94% and a
pecificity of 100% in patients with AFD cardiomyopathy
nd a maximum LV wall thickness of 15 mm; the sign
as less sensitive in patients with milder hypertrophy but
emained highly specific. In the present study, the overall
ensitivity was only 35% (Fig. 1), rising to 44% in
atients with a maximum LV wall thickness of 15 mm.
mportantly, this feature was present in 21% of patients
ithout AFD (Fig. 2) and there was poor inter- and
ntraobserver agreement, reflecting the inherent subjec-
ivity of the binary sign using conventional 2D grayscale
nalysis and the likelihood that in many cases the “sign”
s no more than an ultrasonic artefact.
The study design required that no adjustment of gain
nd compression was made between reviews, but we
nticipate that the binary sign is also likely to be affected
y image quality, gain settings, imaging software, and the
haracteristics of individual ultrasound systems. In conclu-
ion, the binary endocardial appearance is poorly reproduc-
ble and lacks sufficient sensitivity and specificity to be used
Figure 2 Apical View in a
Hypertrophic Cardiomyopathy Patient
A binary endocardial appearance (arrow) is seen.s an echocardiographic screening tool for AFD.
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